{"id":40,"date":"2025-01-22T22:11:18","date_gmt":"2025-01-22T22:11:18","guid":{"rendered":"https:\/\/mrivas.su.domains\/gbe\/?page_id=40"},"modified":"2025-10-30T16:15:13","modified_gmt":"2025-10-30T16:15:13","slug":"curriculum-vitae-cv","status":"publish","type":"page","link":"https:\/\/mrivas.su.domains\/gbe\/curriculum-vitae-cv\/","title":{"rendered":"Curriculum Vitae\/CV"},"content":{"rendered":"\n
<\/span>
\n
\n
\n
\n
\"\"<\/figure>\n\n\n\n

Elements of Life by Augusto Silva Gomez<\/em><\/p>\n\n\n\n

My name is Manuel A. Rivas. I am an Assistant Professor in the Department of Biomedical Data Science<\/a> at Stanford University<\/a>.<\/p>\n\n\n\n

I’ve led a team of PhD students, postdocs, and staff scientists at Stanford. We focus on developing statistical and computational methods for the analysis of population-scale datasets. Our goals are to:<\/p>\n\n\n\n

    \n
  1. Generate effective therapeutic hypotheses from human genetic data;<\/li>\n\n\n\n
  2. Train risk prediction models for rare and common diseases;<\/li>\n\n\n\n
  3. Develop artificial intelligence tools for tumor board discussions of rare disease patients;<\/li>\n\n\n\n
  4. Create optimized algorithms for population-scale datasets.<\/li>\n<\/ol>\n<\/div>\n<\/div>\n\n\n\n
    <\/div>\n\n\n\n
    \n
    \n
    \"\"<\/figure>\n\n\n\n

    Google Scholar<\/a> (h-index 64: Citations: 70,513, i10-index: 118)
    LinkedIn<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    Academic History<\/strong><\/p>\n\n\n\n

    2016 to Present <\/strong>Assistant Professor, University Tenure Line, Department of Biomedical Data Science, Stanford University, Stanford, USA<\/p>\n\n\n\n

    2010 to 2015<\/strong> DPhil, Nuffield Department of Clinical Medicine, Human Genetics, University of Oxford, Oxford, UK<\/p>\n\n\n\n

    2004 to 2008<\/strong> B.S. Mathematics, Massachusetts Institute of Technology, Cambridge, MA, USA<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Scholarships and Honors<\/strong><\/p>\n\n\n\n

    2025 <\/strong>MIT MITES<\/a> Innovator Award. Background profile<\/a>. <\/p>\n\n\n\n

    2017<\/strong> Regional Prize B3 Panama<\/p>\n\n\n\n

    2016 <\/strong>NDM Graduate Prize Winner, University of Oxford<\/p>\n\n\n\n

    2010<\/strong> NDM Osler Award Winner, University of Oxford<\/p>\n\n\n\n

    2010 <\/strong>Clarendon Scholarship, University of Oxford<\/p>\n\n\n\n

    2004 to 2008 <\/strong>Gates Millenium scholarship, Bill and Melinda Gates Foundation<\/p>\n\n\n\n

    2004 <\/strong>Exxon Mobil State and National Scholar, Exxon Mobil<\/p>\n\n\n\n

    2004 <\/strong>Ford Foundation Scholastic Award<\/p>\n\n\n\n

    2004 <\/strong>Advanced Placement National Scholar <\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Secured Funding<\/strong><\/p>\n\n\n\n

    2024 to 2027 <\/strong>Award from the Advanced Research Projects Agency for Health (ARPA-H<\/a>). Artificial Intelligence for Tumor Board Program<\/em>. Principal Investigator<\/strong>.<\/p>\n\n\n\n

    2021 to 2026 <\/strong>NIH R01 Award from National Institutes of Mental Health. Identifying causal genetic variants and molecular mechanisms impacting mental health<\/em><\/a>. Principal Investigator<\/strong>.<\/p>\n\n\n\n

    2016 to 2020<\/strong> NIH R01 Award from National Human Genome Research Institute. Software for Large-scale inference of biomarkers, rare, and common diseases.<\/em> Principal Investigator<\/strong>.<\/p>\n\n\n\n

    2020<\/strong> Takeda Inc. Mapping the genetics of COVID-19. <\/em>Principal Investigator<\/strong>.<\/p>\n\n\n\n

    2018<\/strong> Sanofi US. Machine learning models for dissecting the genetics of Asthma<\/em>. Principal Investigator<\/strong>.<\/p>\n\n\n\n

    2016 to 2020<\/strong> NHGRI Genome Sequencing Coordinating Center. Sucontract PI. <\/p>\n\n\n\n

    2019 to 2021 <\/strong>NIH R01 Distinguishling clinical and genetic risk of suicide ideation. Subcontract PI. <\/p>\n\n\n\n

    2019 to 2022 <\/strong>NIH NHGRI Center for Multi-ethnic mapping of Mendelian and Complex Diseases. Subcontract PI. <\/p>\n\n\n\n

    Patents<\/strong><\/p>\n\n\n\n

    2024 <\/strong>US Patent #12,100,480 Granted. Assessment of polygenic trait risk via trait components and applications thereof<\/a><\/em>. Inventor<\/strong>. <\/p>\n\n\n\n

    2023 <\/strong>World Patent Application #WO2023212294A1. Angiopoietin-related protein 7-specific antibodies and uses thereof<\/a><\/em>. Co-Founder of Broadwing Bio<\/strong>.<\/p>\n\n\n\n

    2023 <\/strong>World Patent Application #WO2024227154A1. Complement component 3 (c3)-specific antibodies and uses thereof<\/a>. Co-Founder of Broadwing Bio<\/strong>.<\/p>\n\n\n\n

    2021 <\/strong>US Patent Application #17\/079,11. Genetic determination of hormone levels and applications thereof<\/em>.<\/a> Inventor<\/strong>.<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Companies Founded<\/strong><\/p>\n\n\n\n

    2020 to Present<\/strong> Broadwing Bio<\/a>. Envisioning an end to blindness.<\/em> Antibody therapeutics company to treat major causes of adult vision loss guided by genetically validated targets.<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Scientific Advisory Boards<\/strong><\/p>\n\n\n\n

    2024 to present<\/strong> Braveheart Bio<\/a>. Founding advisor<\/em>. Heart disease biotechnology company focused on hypertrophic cardiomyopathy.<\/p>\n\n\n\n

    2018 to 2022<\/strong> Maze Therapeutics<\/a>. Maze Fellow<\/em>. Kidney disease biotechnology company focused on genetically validated targets. <\/p>\n\n\n\n

    2019 <\/strong>Related Sciences<\/a>. Data science driven drug foundry.<\/p>\n\n\n\n

    2018 <\/strong>Paradigm4<\/a>. Data sciences analytics company.<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Employment<\/strong><\/p>\n\n\n\n

    Stanford allows annual leave to its faculty. I took two years of leave during COVID to learn about company formation and building biotechnology companies.<\/em><\/p>\n\n\n\n

    2022 to 2023 <\/strong>Head of Statistical Genetics. Maze Therapeutics.<\/p>\n\n\n\n

    2021 to 2022 <\/strong>VP of Human Genetics. HIBio<\/a>.<\/p>\n\n\n\n

    2014 to 2016<\/strong> Computational Scientist. Broad Institute<\/a>.<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-40","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/pages\/40","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/comments?post=40"}],"version-history":[{"count":23,"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/pages\/40\/revisions"}],"predecessor-version":[{"id":563,"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/pages\/40\/revisions\/563"}],"wp:attachment":[{"href":"https:\/\/mrivas.su.domains\/gbe\/wp-json\/wp\/v2\/media?parent=40"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}